NRD
RVNC

Nebula Research & Development’s Revance Therapeutics, Inc. RVNC Stock Holding History

Nebula Research & Development’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-144,365
Closed -$371K – 1214
2024
Q2 		$371K Sell
144,365
-30,502
-17% -$104K 0.06% 522
2024
Q1 		$860K Buy
174,867
+69,572
+66% +$412K 0.19% 184
2023
Q4 		$926K Buy
+105,295
New +$863K 0.28% 86
2023
Q3 		– Sell
-11,619
Closed -$294K – 689
2023
Q2 		$294K Buy
+11,619
New +$362K 0.22% 213

Other funds holding RVNC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return

Nebula Research & Development's RVNC Position: Q3 2024 in Review

Nebula Research & Development sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2024, closing a stake of 144,365 shares — an estimated $371K sold.

Nebula Research & Development first reported a position in RVNC in Q2 2023 and held it in 4 quarters. The position peaked at $926K in Q4 2023. 201 funds tracked by Wall St. Rank hold RVNC as of Q3 2024.

  • Nebula Research & Development reported no remaining Revance Therapeutics, Inc. position as of Q3 2024 after selling out during the quarter.
  • Nebula Research & Development sold 144,365 Revance Therapeutics, Inc. shares in Q3 2024, an estimated $371K.
  • Nebula Research & Development first reported a position in Revance Therapeutics, Inc. in Q2 2023 and held it in 4 quarters.
  • Nebula Research & Development's Revance Therapeutics, Inc. position peaked at $926K in Q4 2023.
  • 201 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2024.

Based on Nebula Research & Development's 13F filing for Q3 2024, filed 14 Nov 2024.